- Home
- GNSS vs TLSA Comparison
GNSS vs TLSA Comparison
Compare GNSS & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- TLSA
- Stock Information
- Founded
- GNSS 1992
- TLSA 2013
- Country
- GNSS United States
- TLSA United Kingdom
- Employees
- GNSS N/A
- TLSA N/A
- Industry
- GNSS Consumer Electronics/Appliances
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- GNSS Consumer Staples
- TLSA Health Care
- Exchange
- GNSS Nasdaq
- TLSA Nasdaq
- Market Cap
- GNSS 169.5M
- TLSA 87.8M
- IPO Year
- GNSS N/A
- TLSA 2000
- Fundamental
- Price
- GNSS $3.75
- TLSA $1.20
- Analyst Decision
- GNSS Strong Buy
- TLSA
- Analyst Count
- GNSS 3
- TLSA 0
- Target Price
- GNSS $5.08
- TLSA N/A
- AVG Volume (30 Days)
- GNSS 106.7K
- TLSA 145.8K
- Earning Date
- GNSS 12-05-2024
- TLSA 05-10-2024
- Dividend Yield
- GNSS N/A
- TLSA N/A
- EPS Growth
- GNSS N/A
- TLSA N/A
- EPS
- GNSS N/A
- TLSA N/A
- Revenue
- GNSS $27,968,000.00
- TLSA N/A
- Revenue This Year
- GNSS N/A
- TLSA N/A
- Revenue Next Year
- GNSS $138.10
- TLSA N/A
- P/E Ratio
- GNSS N/A
- TLSA N/A
- Revenue Growth
- GNSS N/A
- TLSA N/A
- 52 Week Low
- GNSS $1.51
- TLSA $0.41
- 52 Week High
- GNSS $4.04
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- GNSS 60.29
- TLSA 65.44
- Support Level
- GNSS $3.67
- TLSA $0.83
- Resistance Level
- GNSS $3.94
- TLSA $0.92
- Average True Range (ATR)
- GNSS 0.14
- TLSA 0.09
- MACD
- GNSS -0.02
- TLSA 0.03
- Stochastic Oscillator
- GNSS 77.78
- TLSA 84.52
About GNSS Genasys Inc.
Genasys Inc is a provider of critical communications solutions designed to help keep people safe. The company is engaged in the design, development, and commercialization of directed and multidirectional sound technologies, voice broadcast products and location-based mass messaging solutions for emergency warning and workforce management. Its operating segment includes Hardware and Software. The company generates maximum revenue from the Hardware segment. Geographically, it derives a majority of revenue from the Americas region and also has its presence in the Asia Pacific and Europe, Middle East and Africa.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.